{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:57Z","timestamp":1761101277844},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T00:00:00Z","timestamp":1436745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T00:00:00Z","timestamp":1436745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/bmt.2015.158","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T13:41:18Z","timestamp":1436794878000},"page":"1299-1305","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed\/refractory follicular lymphoma"],"prefix":"10.1038","volume":"50","author":[{"given":"S","family":"Yano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Aotsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Kanto Study Group for Cell Therapy (KSGCT)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,13]]},"reference":[{"key":"BFbmt2015158_CR1","doi-asserted-by":"crossref","unstructured":"The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000; 50: 696\u2013702.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"BFbmt2015158_CR2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin\u2019s Lymphoma. Blood 1997; 89: 3909\u20133918.","journal-title":"Blood"},{"key":"BFbmt2015158_CR3","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780\u20132795.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR4","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986\u20131992.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR5","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u20133732.","journal-title":"Blood"},{"key":"BFbmt2015158_CR6","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579\u20134586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR7","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.V74.7.2579.2579","volume":"74","author":"HC Schouten","year":"1989","unstructured":"Schouten HC, Bierman PJ, Vaughan WP, Kessinger A, Vose JM, Weisenburger DD et al. Autologous bone marrow transplantation in follicular non-Hodgkin\u2019s lymphoma before and after histologic transformation. Blood 1989; 74: 2579\u20132584.","journal-title":"Blood"},{"key":"BFbmt2015158_CR8","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004\u20134013.","journal-title":"Blood"},{"key":"BFbmt2015158_CR9","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","volume":"86","author":"Y Bastion","year":"1995","unstructured":"Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257\u20133262.","journal-title":"Blood"},{"key":"BFbmt2015158_CR10","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","volume":"25","author":"AZ Rohatiner","year":"2007","unstructured":"Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554\u20132559.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR11","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530\u20135536.","journal-title":"Blood"},{"key":"BFbmt2015158_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","volume":"17","author":"T Shea","year":"2011","unstructured":"Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395\u20131403.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015158_CR13","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","volume":"28","author":"KJ Thomson","year":"2010","unstructured":"Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellen long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695\u20133700.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","volume":"95","author":"JL Pi\u00f1ana","year":"2010","unstructured":"Pi\u00f1ana JL, Martino R, Gayoso J, Sureda A, de la Serna J, D\u00edez-Mart\u00edn JL et al. Reduced-intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176\u20131182.","journal-title":"Haematologica"},{"key":"BFbmt2015158_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ajh.23261","volume":"87","author":"Y Ono","year":"2012","unstructured":"Ono Y, Mori T, Kato J, Yamane A, Shimizu T, Kikuchi T et al. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. Am J Hematol 2012; 87: 929\u2013931.","journal-title":"Am J Hematol"},{"key":"BFbmt2015158_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367\u2013369.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015158_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244\u20131253.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y . Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 2013; 48: 452\u2013458.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015158_CR20","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540\u20132544.","journal-title":"Blood"},{"key":"BFbmt2015158_CR21","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Le Gouill","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica 2011; 96: 1128\u20131135.","journal-title":"Haematologica"},{"key":"BFbmt2015158_CR23","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011; 29: 3389\u20133395.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR24","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, B\u00f6ck HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003\u20134008.","journal-title":"Blood"},{"key":"BFbmt2015158_CR25","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336\u20134342.","journal-title":"Blood"},{"key":"BFbmt2015158_CR26","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas. J Clin Oncol 2005; 23: 7565\u20137573.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015158_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","volume":"14","author":"JM Vose","year":"2008","unstructured":"Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008; 14: 36\u201342.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015158_CR28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/bmt.2013.83","volume":"48","author":"SP Robinson","year":"2013","unstructured":"Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al. The outcome of reduced-intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48: 1409\u20131414.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015158_CR29","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt2015158_CR30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","volume":"17","author":"MR Tomblyn","year":"2011","unstructured":"Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete remission or first partial remission. Biol Blood Marrow Transplant 2011; 17: 1051\u20131057.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015158_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.leukres.2014.03.005","volume":"38","author":"V Noriega","year":"2014","unstructured":"Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A et al. Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. Leuk Res 2014; 38: 737\u2013743.","journal-title":"Leuk Res"},{"key":"BFbmt2015158_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","volume":"141","author":"W Ingram","year":"2008","unstructured":"Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008; 141: 235\u2013243.","journal-title":"Br J Haematol"},{"key":"BFbmt2015158_CR33","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1002\/cncr.28243","volume":"119","author":"AM Evens","year":"2013","unstructured":"Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS et al. Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 2013; 119: 3662\u20133671.","journal-title":"Cancer"},{"key":"BFbmt2015158_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","volume":"139","author":"C Cordonnier","year":"2003","unstructured":"Cordonnier C, Chevret S, Legrand M, Rafi H, Dh\u00e9din N, Lehmann B et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003; 139: 8\u201318.","journal-title":"Ann Intern Med"},{"key":"BFbmt2015158_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0609.2010.01541.x","volume":"86","author":"S Riihij\u00e4rvi","year":"2011","unstructured":"Riihij\u00e4rvi S, Taskinen M, Jerkeman M, Lepp\u00e4 S . Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011; 86: 124\u2013128.","journal-title":"Eur J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015158","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:17:07Z","timestamp":1648059427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,13]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFbmt2015158"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.158","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2015,7,13]]},"assertion":[{"value":"6 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}